Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Targeted therapies for DLBCL treatment

Wendy Osborne • 2 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma

Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, highlights targeted therapies as the future of diffuse large B-cell lymphoma (DLBCL) treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Wendy Osborne

Glofitamab and epcoritamab in the real-world setting: a UK multi-center retrospective analysis
2:18
Glofitamab and epcoritamab in the real-world setting: a UK multi-center retrospective analysis
Wendy Osborne • 8 Dec 2024
How to best manage first relapse in DLBCL outside of CAR-T
2:21
How to best manage first relapse in DLBCL outside of CAR-T
Wendy Osborne • 8 Dec 2024
The use of bispecifics for NHL in the UK: what do physicians need to know about using these agents?
1:36
The use of bispecifics for NHL in the UK: what do physicians need to know about using these [...]
Wendy Osborne • 8 Dec 2024
The role of bispecific antibodies in the treatment landscape for R/R DLBCL
2:39
The role of bispecific antibodies in the treatment landscape for R/R DLBCL
Wendy Osborne • 22 Apr 2024

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Wendy Osborne • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Wendy Osborne • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Wendy Osborne • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Wendy Osborne • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals